Category Archives: Topics

Structure’s Topline Ph2 Aleniglipron Data; Ascletis Reports Topline Data from Ph1 Oral GLP-1RA; BI Advances Triple Agonist for Obesity; Wave Announces Ph1 Data from Muscle-Sparing Asset; Lingo Now Available on Android; Medtronic Shifts Exec to MiniMed

A series of cardio-metabolic-related news items has been observed from Structure Therapeutics, Ascletis Pharma, Boehringer Ingelheim, Wave Life Sciences, Abbott, and Medtronic. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Insulet O5 Algorithm Updates; BioAge Ph1 NLRP3i Data

Two cardiometabolic-related news items have been observed: Insulet announced it received 510(k) clearance for updates to the O5 algorithm (view press release); and BioAge Labs announced topline Ph1 data of its NLRP3i (BGE-102) in development for obesity (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

FDA Accepts AZ’s Baxdrostat NDA and MannKind’s sNDA for FUROSCIX in CHF + CKD; Medtronic Full US Launch for Abbott-Partnered CGM; Plozasiran Breakthrough Therapy Designation; New Fractyl Data; WHO Publishes GLP-1RA Guidelines

A series of cardiometabolic-related news items has been observed from AstraZeneca, MannKind, Medtronic, Arrowhead Pharmaceuticals, Fractyl Health, and the WHO. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Lilly Cuts Zepbound Prices; Cagrisema Ph3 Pediatric Obesity Trial; Ascletis Selects Obesity Candidate; Altimmune Replaces CEO; Olazarsen Breakthrough Therapy Designation; New Ph3 Bofanglutide Study; Ikaria Registers Study for Obesity Asset Monotherapy and Combination with Tirzepatide

A series of cardiometabolic-related news items has been observed from Lilly, Novo Nordisk, Ascletis Pharma, Altimmune, Ionis Pharmaceuticals, Gan & Lee Pharmaceuticals, and Ikaria Bioscience. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo Files 7.2mg Wegovy; CMS Cuts Semaglutide Prices; FDA Publishes Marketing Violation Letters

Three cardiometabolic-related news items have been observed: Novo Nordisk submitted its sNDA to FDA for high-dose (7.2mg) Wegovy in obesity (view press release); CMS announced the negotiated prices from the second round of IRA discussions, including Novo’s semaglutide (view press release; view fact sheet); and FDA published promotional activity violation letters from the OPDP (view letters). Below, FENIX provides highlights and insights for the respective news items, including the projected approval timeline for high-dose Wegovy in the US.

This content is for Read Less members only.

Already a member? Log in here

Topline Amycretin Ph2 Data in T2DM; Abbott Libre 3/3+ CGM Issues

Two cardiometabolic-related news items have been observed: Novo announced topline Ph2 amycretin data in T2DM (view press release); and Abbott issued a medical correction for its Libre 3/3+ sensors in the US (view press release). Below, FENIX provides highlights and insights for the respective news items, including the potential readthrough from Novo’s amycretin data.

This content is for Read Less members only.

Already a member? Log in here

Novo Misses Alzheimer’s Endpoint; Merck’s New Ph1 Asset in T2DM

Two cardiometabolic-related news items have been observed: Novo Nordisk announced topline EVOKE data for sema in Alzheimer’s (view press release); and Merck registered a Ph1 study of a new undisclosed oral coformulation in T2DM (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items, including potential readthrough from EVOKE to Lilly’s plans in AD.

This content is for Read Less members only.

Already a member? Log in here

Lilly and Novo Establish New Obesity Channels; Orforglipron CVOT Initiated; Lilly Ph2 Study in Chemo-Induced Nausea and Vomiting

Three cardiometabolic-related news items have been observed: Lilly, Novo, and other partners announced direct-to-employer programs for obesity medications (view article); Lilly initiated a Ph3 CVOT for orforglipron in people with ASCVD and/or CKD (view CT.gov record); and Lilly initiated a Ph2 study of its GIP agonist for chemotherapy-induced nausea and vomiting (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Insulet Development and Commercial Roadmap; 2026 Investor Event

Insulet hosted its 2025 investor event and provided updates across its business, including a development roadmap for Omnipod 6 and the next-gen fully closed-loop system (view webcast; view slides). Below, FENIX provides a summary and insights from the event.

This content is for Read Less members only.

Already a member? Log in here

Mazdutide Ph3 Topline Data; Novartis 2025 Investor Day

Two cardiometabolic-related news items have been observed: Innovent announced topline data from a Ph3 mazdutide (oxyntomodulin) study in China (view press release); and Novartis hosted its “Meet Novartis Management” investor day 2025 (view webcast; view slides). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here